SYNMOSA saw its consolidated revenue reach 575 million NTD in June, representing a 51.5% increase compared to the same period last year and an 8% rise from May. The accumulated consolidated revenue for the first half of the year totaled 3.062 billion NTD, up 16.9% year-on-year.

SYNMOSA highlighted that one of the main growth drivers in the first half was the cardiovascular segment, which achieved high double-digit revenue growth following the acquisition of multiple drug approvals last year. Additionally, the cancer/tumor business unit, which has been aggressively developed over the past two years, delivered outstanding performance with nearly 70% year-on-year revenue growth in the first half.

Starting July, SYNMOSA will strengthen strategic cooperation with a leading South Korean biotech pharmaceutical company to actively expand the biosimilar drug market in Taiwan. The initial focus of the partnership will be on biosimilars targeting major diseases such as autoimmune disorders and tumors, with plans to expand the product portfolio based on market feedback and clinical demand.

This collaboration not only supports SYNMOSA’s deeper presence in autoimmune and oncology treatment areas but also introduces more high-quality, cost-effective medication options to Taiwan’s healthcare system, enhancing the international connectivity and development potential of Taiwan’s biotech industry.

Beyond pharmaceuticals, SYNMOSA’s subsidiary Upright Healthcare, known as Taiwan’s first original manufacturer of effervescent tablets, has shown rapid growth in recent years. Upright Healthcare will showcase several consumer-favored products at the upcoming Asia Biotechnology Exhibition starting July 24.

Looking ahead, SYNMOSA Group will continue to drive steady and diversified growth through three core strategies: organic growth, strategic alliances, and ongoing acquisitions, with operational results already emerging and promising better achievements in the future.

Resource: 健喬6月合併營收達5.7億元 年增51.5％